The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK

Objective  To assess the potential epidemiological and economic impact of a prophylactic quadrivalent human papillomavirus (HPV) (6/11/16/18) vaccine for preventing cervical cancer, cervical intraepithelial neoplasia grades 2 and 3 (CIN2/3), CIN1 and genital warts.

[1]  E. Barr,et al.  Quadrivalent human papillomavirus vaccine. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  E. Myers,et al.  Abnormal Outcomes Following Cervical Cancer Screening: Event Duration and Health Utility Loss , 2007, Medical decision making : an international journal of the Society for Medical Decision Making.

[3]  C. Wheeler,et al.  Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials , 2007, The Lancet.

[4]  Erik J. Dasbach,et al.  Model for Assessing Human Papillomavirus Vaccination Strategies , 2007, Emerging infectious diseases.

[5]  S Gallivan,et al.  Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK , 2006, British Journal of Cancer.

[6]  G. Krogh,et al.  High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up , 2006, British Journal of Cancer.

[7]  Elamin H Elbasha,et al.  Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. , 2006, Epidemiologic reviews.

[8]  D. Wiley,et al.  Human papillomavirus: the burden of infection. , 2006, Obstetrical & gynecological survey.

[9]  W. Edmunds,et al.  Modeling Future Changes to the Meningococcal Serogroup C Conjugate (MCC) Vaccine Program in England and Wales , 2006, Human vaccines.

[10]  A. Galvani,et al.  Vaccination against multiple HPV types. , 2005, Mathematical biosciences.

[11]  Cosette M Wheeler,et al.  Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.

[12]  N. Kiviat,et al.  Development and duration of human papillomavirus lesions, after initial infection. , 2005, The Journal of infectious diseases.

[13]  Xavier Castellsagué,et al.  Against which human papillomavirus types shall we vaccinate and screen? the international perspective , 2004, International journal of cancer.

[14]  P. Langley,et al.  The costs of treating external genital warts in England and Wales: a treatment pattern analysis , 2004, International journal of STD & AIDS.

[15]  Z. Philips,et al.  An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme , 2004, British Journal of Cancer.

[16]  J Chilcott,et al.  Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis. , 2004, Health technology assessment.

[17]  David Parkin,et al.  Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. , 2004, Health economics.

[18]  W. Edmunds,et al.  Economic Evaluation of Vaccination Programs: The Impact of Herd-Immunity , 2003, Medical decision making : an international journal of the Society for Medical Decision Making.

[19]  N. Kitchin,et al.  Universal hepatitis B vaccination of UK adolescents: a feasibility and acceptability study. , 2002, Communicable disease and public health.

[20]  Almut Scherer,et al.  Mathematical models of vaccination. , 2002, British medical bulletin.

[21]  Mark A. Miller,et al.  Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. , 2000, JAMA.

[22]  D J Nokes,et al.  Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. , 1999, Statistics in medicine.

[23]  D. Whynes,et al.  Stage-specific treatment costs for cervical cancer in the United Kingdom. , 1998, European journal of cancer.

[24]  M. Botcherby,et al.  Changes in HPV infection in patients with anogenital warts and their partners. , 1993, Genitourinary medicine.

[25]  Bob Erens,et al.  National Survey of Sexual Attitudes and Lifestyles II: reference tables and summary report. , 2003 .